

Financial Tear Sheet

Corporate Profile

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is in Princeton, NJ and the Ireland Headquarters is in Dublin, Ireland.

Primary IR Contact

Nichol Ochsner
 Executive Director, Investor
 Relations & Corporate
 Communications
Phone: 732-754-2545
E-mail:
nochsner@aralez.com

Stock Performance

ARLZ (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.48
Change (%)	▼ 0.08 (5.13%)
Volume	450,082
52 Week Low	\$0.95
Market Cap	\$104,284,081
Rolling EPS	-1.67
PE Ratio	0
Shares Outstanding	66,848,770

Data as of 10/17/17 1:14 p.m. ET



Recent Headlines & Events

- 08/09/17 [Aralez Reports Second Quarter 2017 Financial Results](#)
- 07/24/17 [Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017](#)
- 06/27/17 [Aralez Announces District Court Decision to Uphold VIMOVO \(Naproxen/Esomeprazole Magnesium\) Patents](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
10/04/17	4
09/12/17	CT ORDER
08/09/17	10-Q
08/09/17	8-K

Corporate Governance

Neal F. Fowler

Arthur S. Kirsch

Kenneth B. Lee, Jr.

Seth A. Rudnick, M.D.

F. Martin Thrasher

Adrian Adams

Rob Harris

Data provided by Nasdaq. Minimum 15 minutes delayed.